Posted on: 29/01/2026

Upcoming Life Sciences Investor Day Spotlighting Breakout Australian Companies

Coming soon in February, we are partnering with Wholesale Investor to host the inaugural Life Sciences Investor Day at Emergence, a premier investment conference for high-net-worth, family offices and professional investors.

Wholesale Investor’s CEO Steve Torso believes its going to be an important day and the centrepiece of Emergence 2026 – and it’s sold out already.

“In 17 years of connecting investors with opportunities, life sciences now sits alongside AI and robotics as one of the themes I am most bullish on.

“Breakout life sciences and medical technology companies on the ASX have reminded the market what happens when great science meets the right capital, timing, and execution. The gap between early validation and global scale is shrinking, and the upside is becoming increasingly asymmetric,” Torso said.

Emergence 2026 Day 1 is featuring 25 companies across biotech, medtech and devices, healthcare and pharmaceuticals.

During the day, two panel sessions will feature leading success stories and investment minds to help investors build their own investment thesis for approaching this unique opportunity.

Some of the featured companies taking part in the life sciences day include:

Chimeric Therapeutics (ASX:CHM) — is a clinical-stage Australian biotechnology company advancing a diversified, FDA-fast-tracked portfolio of CAR T and NK cell therapies for solid tumours and blood cancers.
Eyerising International — A light-based medical device platform for non-invasive myopia (nearsightedness) control, combining patented technology addressing the growing global vision health issue safely and conveniently.
Biotome — Peptide diagnostics platform enabling ultra-sensitive, patentable tests, preventing disease through detection.
Lindo Life Science — Backed by the Mayo Clinic, a light-based medical device preventing ventilator pneumonia using antimicrobial blue-light technology.
Ventora Medical — Transforming neonatal respiratory care with continuous, accurate, non-invasive airway pressure monitoring.
Percheron Therapeutics Limited (ASX: PER) — Developing differentiated immuno-oncology therapies activating immune systems to treat cancer globally.
Recce Pharmaceuticals Ltd (ASX: RCE, FSE:R9Q) — Developing synthetic anti-infectives to combat antibiotic-resistant superbugs and emerging viral pathogens.
Medigrowth — Advancing plant-based medicine through research, education, and clinically validated natural wellness solutions.
Zaplutus — Next-generation wearable delivering continuous diagnostic-quality vital signs via automated cuff-less monitoring.
Ferronova Pty Ltd — Precision-guided cancer surgery using nanoparticles and AI to prevent recurrence.
Elemental IV — Establishing Australia’s sovereign sterile IV fluids and ready-to-use medicines manufacturing.
BCS2 — AI upgrades off-patent drugs into fast-acting, highly bioavailable super-generics oral formulations.
Cartherics Pty Ltd — Off-the-shelf engineered NK cell therapies targeting ovarian cancer and severe endometriosis.

These companies are focused on clinical validation, commercial traction and global ambition.

MTPConnect is backing this initiative through the MTPConnect Investor Ready Program which aims to enhance life science companies’ readiness for investment and connecting companies directly with Wholesale Investor’s network of over 45,000 investors. Through the program which opened in November 2025, MTPConnect has been assisting participating companies with their capital raising requirements through a curated package of activities provided by Wholesale Investor.

Event Details:

Date: Wednesday, 18 February 2026
Venue: Four Seasons Hotel, Sydney
Audience: 750+ HNWIs, family offices, and institutional investors focused on life sciences